// App-Quantinova.ai

OR1‐001 : Phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma: analysis of longer follow‐up on CheckMate 205 including brentuximab vedotin‐naïve patients

Researchers

Presenter

  • JM Timmerman

Principal Investigators

  • A Younes

  • A Santoro

  • P Armand

  • M Fanale

  • GP Collins

  • V Ratanatharathorn

  • J Kuruvilla

  • JB Cohen

  • KJ Savage

  • M Trneny

  • JP de Boer

  • MA Shipp

  • S Rodig

  • PL Zinzani

  • K Kato

  • A Sumbul

  • S Ansell

Medical Centers

  • University of Southern California, Los Angeles, California, United States

  • University of Cologne, Cologne, DE, Germany

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Humanitas Cancer Center, Humanitas University, Rozzano (MI), Italy

  • Dana-Farber Cancer Institute, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Winship Cancer Institute of Emory University,Atlanta, GA,Vereinigte Staaten

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Brigham and Womens Hospital, Boston, MA, United States

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Mayo Clinic, Rochester, United States

Locations

  • United States

  • Germany

  • Italy

  • United Kingdom

  • Canada

  • Czech Republic

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT02181738

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved